Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-62 for mild autonomous cortisol secretion due to adrenal adenoma
ISRCTN42727091Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Mild hypercortisolism (SCS) comparing SPI-62 with Placebo (2 arms). Primary endpoint: Glucose disposal during hyperinsulinaemic euglycaemic clamp. Started Mar 2024; status: active, not recruiting.
02
Drugs
clofutriben
03
Conditions
Mild hypercortisolism (SCS)
Beyond the preview
Go deeper on ISRCTN42727091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42727091.